To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6Á4 was 82Á2% vs. 95Á7% with NLR <6Á4 (P < 0Á001). Similarly, 2-year FFP was 84Á3% for patients with PLR ≥266Á2 vs. 96Á1% with PLR <266Á2 (P = 0Á003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0Á001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0Á001).
In the era of treatment de-escalation for stage I and II classical Hodgkin lymphoma (cHL), appropriate risk-stratification of those patients with high relapse risk is critical to identify those for whom treatment de-escalation is inappropriate. Positron emission tomography (PET)-based responseadapted therapy is promising; however, the recent UK RAPID and EORTC/LYSA/FIL H10 trials demonstrated the inferiority of omitting radiation in early stage patients who develop a negative PET after ABVD (doxorubicin, bleomycin, vincristine; dacarbazine) chemotherapy (Radford et al, 2015; Andre et al, 2017) , suggesting that PET alone may not be sufficient risk stratification.
Consequently, there is interest in identifying simple, low cost laboratory assessments that improve current risk stratification approaches in early-stage cHL. Recently, the neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) ratios have been demonstrated to be prognostic in some solid malignancies. NLR has been shown to be a prognostic factor in diffuse large B-cell lymphoma (DLBCL) (Porrata et al, 2010; Ho et al, 2015; Keam et al, 2015) , while PLR was recently shown to be prognostic in Natural Killer/T-cell lymphoma (Wang et al, 2014) . However, few studies have examined the potential prognostic value of NLR and PLR in cHL. The goal of this study was to examine our institutional experience to determine whether NLR and PLR can serve as prognostic indicators for early stage cHL and should be included in future risk-stratification approaches.
Methods and materials

Study cohort and NLR/PLR assessment
This retrospective analysis of early-stage cHL patients was approved by the MD Anderson institutional review board. We identified 338 consecutively treated patients with stage I or II cHL treated between 2002 and 2015. For study inclusion, patients must have had pre-treatment complete blood count (CBC) with differential, from which absolute neutrophil (ANC), lymphocyte (ALC), and platelet counts prior to chemotherapy were acquired. These values were subsequently used to calculate NLR and PLR values (Roxburgh & McMillan, 2010; Proctor et al, 2011) . The NLR was derived by dividing the ANC by the ALC at diagnosis. The PLR was similarly derived by dividing the absolute platelet count by the ALC at diagnosis.
Endpoints and statistical analysis
Optimal cut-off points for both NLR and PLR were determined by both receiver operative curve (ROC) analysis and the method of Liu (2012) (Data S1). The primary endpoint was freedom from progression (FFP), which was defined as relapsed or refractory disease. Relapse was defined as disease recurrence found on restaging PET/computed tomography (CT) following a minimum disease-free interval of 3 months. Refractory disease was designated by the treating medical oncologist following a restaging PET/CT within 3 months following the end of treatment. Time to event was calculated from date of pathological diagnosis to the date of progression. Patients who survived were censored at their last follow-up date. Cox regression was used to identify variables associated with FFP. All P-values were two-sided, with values of ≤0Á05 considered to be significant.
Results and discussion
Baseline characteristics of the 338 stage I/II patient cohort are shown in Table S1 . Median age at diagnosis was 32 years [interquartile range (IQR) 24-42] with a median follow-up Table I . Pre-treatment characteristics stratified on NLR and PLR values. of 5 years (IQR 2Á9-7Á8). Most patients (n = 286, 84Á6%) had Ann Arbor stage II disease and were classified as earlyunfavourable (n = 224, 66Á3%) using the German Hodgkin Study Group criteria (Engert et al, 2010) . Two-year FFP and OS for the entire study cohort was 91Á7% and 96Á8%, respectively. The median NLR was 4Á1 (IQR 2Á5-7Á1), and the median PLR was 214Á2 (IQR 148Á4-334Á8, Table S1 ). Both NLR and PLR were significantly associated with disease progression on simple logistic regression (P < 0Á01). Both ROC analysis and the method of Liu (2012) were in agreement in determining optimal cut-off points for NLR and PLR that predicts for disease progression (Data S1). The cut-off point for NLR was 6Á4 [95% confidence interval (CI): 4Á14-8Á72] and 266Á2 (95% CI: 182Á81-349Á53) for PLR. Upon dichotomizing the cohort based on these cut-off points, we confirmed that elevated NLR and PLR values were associated with worse FFP. Two-year FFP for patients with an NLR ≥6Á4 was 82Á2% compared to 95Á7% in patients with an NLR < 6Á4 (P < 0Á001, Figure S1a ). Similarly, 2-year FFP was 84Á3% for patients with a PLR ≥ 266Á2 and 96Á1% in patients with a PLR < 266Á2 (P = 0Á003, Figure S1b ).
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We next examined whether NLR and PLR values stratified on the above cut-off points are significantly associated with clinical factors (Table I) . Patients with elevated NLR and PLR levels were more likely to have adverse pre-treatment factors, e.g. stage II disease, B symptoms, or bulky disease ( Table I ), suggesting that NLR and PLR can serve as biomarkers for adverse features. Furthermore, we found that both NLR [Hazard ratio (HR): 1Á19, 95% CI: 1Á07-1Á32, P = 0Á001) and PLR (HR: 1Á05, 95% CI: 1Á03-1Á08, P < 0Á001) were significantly associated with worse FFP on univariate analysis (Table II) . We next performed multivariate modelling to determine whether NLR and PLR can serve as independent factors associated with worse FFP. Given the significant multi-collinearity between these assessments in that both incorporate ALC values (Pearson coefficient = 0Á82), both NLR and PLR were not retained in the final model. In the final model, only bulky disease (HR: 4Á20, 95% CI: 1Á82-9Á71, P < 0Á001) and PLR (HR: 1Á04, 95% CI: 1Á01-1Á06, P = 0Á017) continued to be significantly associated with worse FFP (Table II) . NLR did not remain significantly associated with FFP. Collectively, these findings suggest that while both NLR and PLR are significantly associated with worse FFP on univariate analysis, only PLR is an independent prognostic factor of relapse or refractory disease.
We next sought to determine whether post-treatment NLR and PLR values could reliably predict relapse. After excluding patients with refractory disease and those without laboratory values following frontline therapy, 278 patients were available for analysis. However, there were very few relapse events in this subgroup (n = 12, 4Á3%). On simple logistic regression, neither post-treatment NLR nor PLR were significantly associated with relapse (P = 0Á61 for NLR and P = 0Á75 for PLR).
These findings have potentially important clinical and research implications as future endeavours seek to further de-intensity treatment without compromising excellent outcomes in cHL. This is the first study to demonstrate the prognostic value of both pre-treatment NLR and PLR in predicting FFP in early-stage cHL, a critical population for whom treatment de-escalation in selected patients may be appropriate. Therefore, further investigation and validation in additional data sets is warranted.
There is accumulating evidence that NLR and PLR are associated worse prognosis in multiple solid malignancies (Guthrie 2013; Templeton et al, 2014) and non-Hodgkin lymphoma (Porrata et al, 2010; Keam et al, 2015) (Wang et al, 2014) . Recently, two studies have examined the influence of NLR on outcomes in HL. Koh et al (2012) found that NLR values >4Á3 were associated with worse OS in advanced stage cHL subgroups but not in early stage cHL patients. In contrast Marcheselli et al (2016) found that NLR >6 was associated with worse PFS and OS in both early and advanced stage cHL. Importantly, our study differs from these prior analyses in that it focuses on early stage patients, examines both NLR and PLR, and finds that PLR, rather than NLR, is an independent prognostic factor. Our study has several important limitations. First, this study is retrospective and, therefore, subject to inherent limitations and biases. Second, our study population had only 31 events of disease progression, which limited the complexity of our final multivariate model. Consequently, validation of the utility of NLR and PLR in a second data set is needed. Despite these limitations, our experience is unique in that it is a relatively large single institutional experience focusing on early stage cHL and factors associated with disease progression.
In conclusion, pre-treatment NLR and PLR are significantly associated with increased risk of relapse or refractory disease in stage I and II cHL. Elevated levels of these parameters are associated with worse FFP on univariate analysis. However, only PLR remained significantly associated with worse FFP after correcting for the presence of other factors on multivariate analysis. Pre-treatment NLR and PLR represent low-cost, effective supplements to future risk stratification schema that merit further investigation. 
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